Academic Journals Database
Disseminating quality controlled scientific knowledge

99mTc-Glucarate as a potential novel tracer of lung cancer lesions.

Author(s): Gambini, Juan P. | Cabral, Pablo. | Santander, Gianeya. | Canepa, Jorge. | Andruskevicius, Patricia. | Piuma, Lourdes. | Savio, Eduardo. | Delgado, Lucía. | Quagliata,Adriana. | Alonso, Omar.

Journal: Alasbimn Journal
ISSN 0717-4055

Volume: 9;
Issue: 34;
Date: 2006;
Original page

Keywords: 99mTc-Glucarate | lung cáncer diagnosis | 99mTc-Glucarato | diagnóstico cáncer de pulmón.

Lung cancer is the leading cause of cancer-related mortality in the world. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung malignant tumors and it usually presents at the moment of diagnosis as a locally advanced or metastatic disease. Surgery is not indicated in two thirds of them, being chemotherapy (QT) the accepted therapeutic approach. Only 30% of those patients respond to treatment whereas the remaining group will receive antineoplasic drugs without any therapeutic benefit but suffering their adverse effects. In this situation, it would be of clinical relevance to have a functional scintigraphic technique with the potential to evaluate in an early-phase the response to therapy. Our group has developed a clinical protocol to investigate if 99mTc-Glucarate can be used to predict the response to QT in this group of patients. In order to accomplish this objective, we have to previously demonstrate that primary and secondary lesions of NSCLC can accumulate the radiotracer. The present case report describes for the first time in the indexed literature the use of 99mTc-Glucarate as a functional marker of primary and secondary lesions of NSCLC.El cáncer broncopulmonar (CBP) es la primera causa de muerte por cáncer en el mundo. El CBP a células no pequeñas (CBPCNP) representa el 80% de la patología neoplásica pulmonar, presentándose frecuentemente al diagnóstico como localmente avanzando o metastásico. Dos tercios se presentan en etapa avanzada, inoperable, integrando la quimioterapia (QT) el tratamiento. Responden favorablemente 30% de dichos pacientes; los restantes recibirán agentes antineoplásicos sin beneficio terapéutico pero con sus efectos adversos. Ante dicha situación sería de gran relevancia clínica poder contar con una técnica funcional que permitiera evaluar la respuesta a la terapia oncoespecífica. Por tal motivo, nuestro grupo ha desarrollado un protocolo clínico para investigar la capacidad del 99mTc-Glucarato en la evaluación precoz de la respuesta a la QT en este grupo de pacientes. Para ello, es necesario demostrar previamente que las lesiones primarias y secundarias del CBPCNP pueden acumular este trazador. La presente nota clínica describe por vez primera en la literatura indexada la capacidad del 99mTc-Glucarato como marcador funcional de lesiones primarias y metastásicas del CBPCNP.
RPA Switzerland

Robotic Process Automation Switzerland


Tango Rapperswil
Tango Rapperswil